Challenges in Healthcare Transparency and Accountability

The chapter explores the lack of transparency in federal health agencies regarding generic drug exploration and the challenges doctors face in researching non-mainstream pharmaceutical recommendations. It highlights the financial disincentives for studying off-patent and off-label drugs and questions the funding and publication bias in health research. Featuring Dr. Christian Paron's experiences during the COVID crisis, the chapter touches on censorship, fraudulent studies, and the need for effective communication against misinformation.